Skip to main content
Premium Trial:

Request an Annual Quote

OmicaBio, GenobankIo Partner on Tokenized Consent Protocol for Sequencing Study

NEW YORK — OmicaBio, a population genomics startup focused on diversity genomic research in Latin America, said on Tuesday that it has partnered with anonymous DNA test kit provider GenobankIo on the development of a tokenized consent protocol.

According to OmicaBio, it will use GenobankIo's web3 data-management technology to roll out the protocol as part of an effort to sequence 10,000 whole genomes from rare disease patients throughout Mexico and Central America.

Mexico City-based OmicaBio said it has also made an undisclosed investment in GenobankIo as part of the arrangement. Additional terms were not disclosed.

"The aim of this collaboration is to offer research participants unprecedented transparency and traceability over the use of their genomic and clinical data," GenobankIo Founder and CEO Daniel Uribe said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.